Pliant Therapeutics Reports Narrowed Loss, Extends Cash Runway to H2 2028, and Advances Oncology Program

summarizeSummary

Pliant Therapeutics reported strong Q1 2026 financial results with a significantly narrowed net loss and extended its cash runway into the second half of 2028, alongside positive clinical advancements for its lead oncology program.

check_boxKey Events

• Q1 Net Loss Significantly Narrowed

  Net loss reduced to $20.0 million for Q1 2026, compared to $56.2 million in the prior-year quarter, primarily due to lower research and development and general and administrative expenses.

• Cash Runway Extended to H2 2028

  The company reported $172.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, which is expected to fund operations into the second half of 2028.

• Lead Oncology Program Advances to Phase 1b

  Pliant Therapeutics dosed the first participant in FORTIFY, a Phase 1b indication expansion trial for its lead oncology candidate, PLN-101095, ahead of schedule in April.

• Positive Phase 1 Data Presented at AACR

  Updated Phase 1 data for PLN-101095, presented at AACR 2026, highlighted deepening of confirmed responses in patients with immune checkpoint inhibitor-refractory solid tumors.

auto_awesomeAnalysis

This 8-K, furnishing the Q1 2026 earnings press release, delivers significant positive news for Pliant Therapeutics. The company reported a substantially narrowed net loss and drastically reduced operating expenses, leading to an extended cash runway into the second half of 2028. This financial stability is crucial for a clinical-stage biotech. Concurrently, the company announced positive clinical progress for its lead oncology candidate, PLN-101095, including dosing the first patient in a Phase 1b trial ahead of schedule and presenting encouraging updated Phase 1 data at AACR.